Lineage-specific treatments, such as CD19 CAR-T or ALL-type chemotherapy, can eradicate the dominant phenotype while sparing-indeed, favoring the outgrowth of a minor clone along an alternate differentiation trajectory [19,20]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.